Prostate Cancer - Results from #1100

Beyond the Abstract - High intensity focused ultrasound in clinical tumor ablation, by Yufeng Zhou, PhD September 13, 2011

Beyond the Abstract - Watchful waiting and active surveillance approach in patients with low risk localized prostatic cancer: An experience of out-patients clinic with 12-year follow-up, by Sergey Kravchick, MD September 9, 2011

Beyond the Abstract - Disease-specific survival of men with prostate cancer detected during the screening interval: Results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up, by Xiaoye Zhu, MD, et al September 7, 2011

Beyond the Abstract - Reverse stage shift at a tertiary care center: Escalating risk in men undergoing radical prostatectomy, by Vincent P. Laudone, MD and Jonathan Silberstein, MD September 6, 2011

Beyond the Abstract - Survival is associated with time to reach PSA nadir (DAN) and the ratio DAN/nadir value after androgen deprivation for prostate cancer, by Jacques Irani, MD August 25, 2011

Beyond the Abstract - Bone scan overuse in staging of prostate cancer: An analysis of a Veterans Affairs cohort, by Roland Palvolgyi August 17, 2011

Beyond the Abstract - Effect of testosterone administration to men with prostate cancer is unpredictable: A word of caution and suggestions for a registry, Alvaro Morales, MD, FRCS(C), FACS August 15, 2011

Beyond the Abstract - Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments, by Jeri Kim, MD, Patricia Parker, PhD, and Douglas Boyd, PhD August 11, 2011

Beyond the Abstract - Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up, by Eric Barret, MD August 9, 2011

Beyond the Abstract - The health and well-being of prostate cancer patients versus male-to-female transsexuals on androgen deprivation therapy: A qualitative study with comments on expectations and estrogen, by Richard Wassersug, PhD July 19, 2011

Beyond the Abstract - Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy, by Richard J. Wassersug, et al July 14, 2011

Beyond the Abstract - Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer, by Joey Cheung July 13, 2011

Beyond the Abstract - Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden, by Benny Holmström, et al. July 11, 2011

Beyond the Abstract - Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: The results from the REDUCE study, by Hideyuki Akaza, MD July 4, 2011

Beyond the Abstract - Regression of prostate tumors upon combination of hormone ablation therapy and Celecoxib in vivo, by Per Borgström, PhD, et al. July 1, 2011

Beyond the Abstract - Endoglin suppresses human prostate cancer metastasis, by Michael Breen, MD, PhD Candidate and Raymond Bergan, MD June 28, 2011

Beyond the Abstract - Adjuvant medical therapy for prostate cancer, by Thomas W. Flaig, MD June 24, 2011

Beyond the Abstract - Does valproic acid induce neuroendocrine differentiation in prostate cancer? by Abhinav Sidana, MD June 23, 2011

Beyond the Abstract - Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs, by Sumith A. Kularatne, PhD and Philip S. Low, PhD June 16, 2011

Beyond the Abstract - Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer, by George E. Sandusky, DVM, PhD June 6, 2011

Page 56 of 57